7xm bangladesh app

7xm bangladesh app Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Townsquare to Participate in Upcoming Investor Conferences

Saudi Arabia shares higher at close of trade; Tadawul All Share up 0.20%None

LAS VEGAS — There are three races remaining in the Formula 1 season and Max Verstappen of Red Bull is close to a fourth consecutive world championship, which can wrap up Saturday night at the Las Vegas Grand Prix. All is not smooth sailing headed into this final month of racing: "It was a bit of a surprise, I think, for everybody," said Mercedes driver George Russell, a GPDA director. "It's a hell of a lot of pressure now onto the new race director (with) just three races left. Often, as drivers, we probably feel like we're the last to find out this sort of information." The Andretti team is expected to receive F1 approval to join the grid, albeit without Michael Andretti, who has scaled back his role dramatically since the IndyCar season ended in September. Many drivers, particularly seven-time champion Lewis Hamilton, have been at odds with FIA President Mohammed Ben Sulayem since his election following the 2021 season finale. In the GDPA statement, they reminded the sanctioning body "our members are adults" who don't need lectures and fines on foul language or jewelry bans, and simply want fair and consistent race control. There's been no response from Ben Sulayem, and won't be this weekend since he does not attend the LVGP. He will be at Qatar and the finale in Abu Dhabi next month. Hamilton doesn't think all the behind-the-scenes changes will be a fan topic as the season comes to a close. But he noted that consistency from race control is all the drivers have asked for, while throwing his support behind Domenicali and the job Maffei has done in growing F1 since Liberty took over. "I really hope Stefano is not leaving because he's been so instrumental in changes and progress to this whole thing," Hamilton said. "And he knows the sport as well as anyone. But all good things do come to an end, and whoever they put into place, I just hope they are like-minded. But sometimes you have to shake the trees." That's just what happened with the surprise departure of race director Wittich. Although drivers have been unhappy with race officiating this season and held a private GPDA meeting in Mexico City, Russell said they had no prior warning Wittich was out. The race director is the referee each weekend and Wittich has been in charge since 2022, when Michael Masi was fired following the controversial 2021 season-ending, championship-altering finale at Abu Dhabi. Now the man in charge for the final three races is Rui Marques, the Formula 2 and Formula 3 race director. Las Vegas, which overcame multiple stumbling blocks in last year's debut before putting on one of the best races of the season, is a difficult place to start. Verstappen can win his fourth title by simply scoring three points more than Lando Norris of McLaren. "It's a bit weird with three races to go to do that," Verstappen said. "It doesn't matter if you're positive or negative about certain things. I thought in Brazil there was definitely room for improvement, for example. It's still a bit weird having to now then deal with a different race director." Charles Leclerc of Ferrari wondered why the move was made with only three races to go. "To do it so late in the season, at such a crucial moment of the season, it could have probably been managed in a better way," he said. The drivers have consistently asked for clearer guidelines in the officiating of races, specifically regarding track limits and racing rules. The drivers have no idea how Marques will officiate, highlighting a disconnect between the competitors and Ben Sulaymen's FIA. "We just want to be transparent with the FIA and have this dialogue that is happening," Russell said. "And I think the departure of Niels is also a prime example of not being a part of these conversations." The GDPA statement made clear the drivers do not think their voice is being heard. "If we feel we're being listened to, and some of the changes that we are requesting are implemented, because ultimately we're only doing it for the benefit of the sport, then maybe our confidence will increase," Russell said. "But I think there's a number of drivers who feel a bit fed up with the whole situation. It only seems to be going in the wrong direction." He also said the relationship between the drivers and the FIA seems fractured. "Sometimes just hiring and firing is not the solution," he said. "You need to work together to improve the problem." Norris, who has battled Verstappen this year with mixed officiating rulings, said "obviously things are not running as smoothly as what we would want." Marques has his first driver meeting ahead of Thursday night's two practice sessions and then three weeks to prove to the competitors he is up for the job. Carlos Sainz Jr., who will leave Ferrari for Williams at the end of the season, hopes the drama doesn't distract from the momentum F1 has built over the last five years. "I think Formula 1 is in a great moment right now and all these rumors, I think in every team, every job, there's job changes," he said. "It's not big drama. I'm a big fan of the people you mentioned, they've done an incredible job in Formula 1 and Formula 1 is what it is thanks to these people. But it's just so emotional, especially the Stefano one. The only one that has a real effect is the race director. But I think if he does a good job, it should be transparent and nothing big." Get local news delivered to your inbox!

Photo: The Canadian Press In this photo provided by Ukraine's 24th Mechanised Brigade press service, servicemen of the 24th Mechanised Brigade fire 120mm mortar towards Russian positions near Chasiv Yar town, in Donetsk region, Ukraine, Tuesday, Nov. 19, 2024. (Oleg Petrasiuk/Ukrainian 24th Mechanised Brigade via AP) The Kremlin fired a new intermediate-range ballistic missile at Ukraine on Thursday in response to Kyiv's use this week of American and British missiles capable of striking deeper into Russia, President Vladimir Putin said. In a televised address to the country, the Russian president warned that U.S. air defense systems would be powerless to stop the new missile, which he said flies at ten times the speed of sound and which he called the Oreshnik — Russian for hazelnut tree. He also said it could be used to attack any Ukrainian ally whose missiles are used to attack Russia. “We believe that we have the right to use our weapons against military facilities of the countries that allow to use their weapons against our facilities,” Putin said in his first comments since President Joe Biden gave Ukraine the green light this month to use U.S. ATACMS missiles to strike at limited targets inside Russia. Pentagon deputy press secretary Sabrina Singh confirmed that Russia’s missile was a new, experimental type of intermediate range missile based on it’s RS-26 Rubezh intercontinental ballistic missile. “This was new type of lethal capability that was deployed on the battlefield, so that was certainly of concern," Singh said, noting that the missile could carry either conventional or nuclear warheads. The U.S. was notified ahead of the launch through nuclear risk reduction channels, she said. The attack on the central Ukrainian city of Dnipro came in response to Kyiv's use of longer-range U.S. and British missiles in strikes Tuesday and Wednesday on southern Russia, Putin said. Those strikes caused a fire at an ammunition depot in Russia's Bryansk region and killed and wounded some security services personnel in the Kursk region, he said. “In the event of an escalation of aggressive actions, we will respond decisively and in kind,” the Russian president said, adding that Western leaders who are hatching plans to use their forces against Moscow should “seriously think about this.” Putin said the Oreshnik fired Thursday struck a well-known missile factory in Dnipro. He also said Russia would issue advance warnings if it launches more strikes with the Oreshnik against Ukraine to allow civilians to evacuate to safety — something Moscow hasn’t done before previous aerial attacks. Kremlin spokesman Dmitry Peskov initially said Russia hadn’t warned the U.S. about the coming launch of the new missile, noting that it wasn't obligated to do so. But he later changed tack and said Moscow did issue a warning 30 minutes before the launch. Putin's announcement came hours after Ukraine claimed that Russia had used an intercontinental ballistic missile in the Dnipro attack, which wounded two people and damaged an industrial facility and rehabilitation center for people with disabilities, according to local officials. But American officials said an initial U.S. assessment indicated the strike was carried out with an intermediate-range ballistic missile. Ukrainian President Volodymyr Zelenskyy said in a Telegram post that the use of the missile was an "obvious and serious escalation in the scale and brutality of this war, a cynical violation of the UN Charter.” He also said there had been “no strong global reaction” to the use of the missile, which he said could threaten other countries. “Putin is very sensitive to this. He is testing you, dear partners,” Zelenskyy wrote. “If there is no tough response to Russia’s actions, it means they see that such actions are possible.” The attack comes during a week of escalating tensions, as the U.S. eased restrictions on Ukraine's use of American-made longer-range missiles inside Russia and Putin lowered the threshold for launching nuclear weapons. The Ukrainian air force said in a statement that the Dnipro attack was launched from Russia’s Astrakhan region, on the Caspian Sea. “Today, our crazy neighbor once again showed what he really is,” Zelenskyy said hours before Putin's address. “And how afraid he is.” Russia was sending a message by attacking Ukraine with an intermediate-range ballistic missile capable of releasing multiple warheads at extremely high speeds, even if they are less accurate than cruise missiles or short-range ballistic missiles, said Matthew Savill, director of military sciences at the Royal United Services Institute, a London-based think tank. “Why might you use it therefore?” Savill said. "Signaling — signaling to the Ukrainians. We’ve got stuff that outrages you. But really signaling to the West ‘We’re happy to enter into a competition around intermediate range ballistic missiles. P.S.: These could be nuclear tipped. Do you really want to take that risk?’” Military experts say that modern ICBMs and IRBMs are extremely difficult to intercept, although Ukraine has previously claimed to have stopped some other weapons that Russia described as “unstoppable,” including the air-launched Kinzhal hypersonic missile. David Albright, of the Washington-based think tank the Institute for Science and International Security, said he was “skeptical” of Putin’s claim, adding that Russian technology sometimes “falls short.” He suggested Putin was “taunting the West to try to shoot it down ... like a braggart boasting, taunting his enemy.” Earlier this week, the Biden administration authorized Ukraine to use the U.S.-supplied, longer-range missiles to strike deeper inside Russia — a move that drew an angry response from Moscow. Days later, Ukraine fired several of the missiles into Russia, according to the Kremlin. The same day, Putin signed a new doctrine that allows for a potential nuclear response even to a conventional attack on Russia by any nation that is supported by a nuclear power. The doctrine is formulated broadly to avoid a firm commitment to use nuclear weapons. In response, Western countries, including the U.S., said Russia has used irresponsible nuclear rhetoric and behavior throughout the war to intimidate Ukraine and other nations. White House press secretary Karine Jean-Pierre said Thursday that Russia’s formal lowering of the threshold for nuclear weapons use did not prompt any changes in U.S. doctrine. She pushed back on concerns that the decision to allow Ukraine to use Western missiles to strike deeper inside Russia might escalate the war. ?They’re the ones who are escalating this,” she said of the Kremlin — in part because of a flood of North Korean troops sent to the region. More than 1,000 days into war, Russia has the upper hand, with its larger army advancing in Donetsk and Ukrainian civilians suffering from relentless drone and missile strikes. Analysts and observers say the loosening of restrictions on Ukraine's use of Western missiles is unlikely to change the the course of the war, but it puts the Russian army in a more vulnerable position and could complicate the logistics that are crucial in warfare. Putin has also warned that the move would mean that Russia and NATO are at war. “It is an important move and it pulls against, undermines the narrative that Putin had been trying to establish that it was fine for Russia to rain down Iranian drones and North Korean missiles on Ukraine but a reckless escalation for Ukraine to use Western-supplied weapons at legitimate targets in Russia,” said Peter Ricketts, a former U.K. national security adviser who now sits in the House of Lords.None

What to Consider When Purchasing a Mobile Phone Signal Booster for Basements or Underground Parking Lots

Adam22 Compares Kendrick Lamar To Donald Trump With Their “Cult” FanbasesAs part of a national “moonshot” to cure blindness, researchers at the CU Anschutz Medical Campus will receive as much as $46 million in federal funding over the next five years to pursue a first-of-its-kind full eye transplantation. “What was once a dream — to cure blindness — is potentially within our grasp,” the campus’ chancellor, Don Elliman, said during a press conference Monday morning. The University of Colorado team, led by researcher Dr. Kia Washington, was one of four in the United States that received funding awards from the , or ARPA-H. The CU-based group will focus on achieving the first-ever vision-restoring eye transplant by using “novel stem cell and bioelectronic technologies,” according to a news release announcing the funding. The four teams will work alongside each other on distinct approaches, though officials said teams would likely collaborate and eventually may merge depending on which research avenues show the most promise toward achieving the ultimate goal of curing blindness. Dr. Calvin Roberts, who will oversee the broader project for ARPA-H, said the agency wanted to take multiple “shots on goal” to ensure progress. “In the broader picture, achieving this would be probably the most monumental task in medicine within the last several decades,” said Dr. Daniel Pelaez of the University of Miami Bascom Palmer Eye Institute, which also received ARPA-H funding. Pelaez is the lead investigator for that team, which pursued new procedures to successfully remove and preserve eyes from donors. He told The Denver Post that only four organ systems have not been successfully transplanted: the inner ear, the brain, the spinal cord and the eye. All four are part of the central nervous system, which does not repair itself when damaged. If researchers can successfully transplant the human eye and restore vision to the patient receiving it, that could help unlock deeper discoveries about fixing damage to the brain and spine, as well as addressing hearing loss, Pelaez said. To do it, researchers must successfully remove and preserve eyes from donors, and then successfully connect and repair the optical nerve, which takes information from the eye and tells the brain what the eye sees, between the donor’s eye and the recipient’s brain. Washington, the lead CU researcher, said she and her colleagues have already completed the eye transplant procedure — albeit without vision restoration — in rats. Now they’re set to proceed to larger animals, Washington said. A team at New York University on a human patient in November 2023, though the procedure — while successful — did not restore the patient’s vision. Washington said developing a small-animal model, even without vision restoration, was a key milestone in advancing the project. The goal is to fully restore the optic nerve — which carries visual information from the eye to the brain — and to fully connect a patient’s brain with a donor’s eye. The CU team will work on large animals next to advance “optic nerve regenerative strategies,” the school said, as well as to study immunosuppression, which is critical to ensuring that patients’ immune systems don’t reject a donated organ. The goal is to eventually advance to human trials. ARPH-A, created two years ago, will oversee the teams’ work in the coming years. Researchers at 52 institutions nationwide will contribute to the teams. The CU-led group will include researchers from the University of Southern California, the University of Wisconsin, Indiana University and Johns Hopkins University, as well as from . The total funding available for the teams is $125 million, ARPA-H officials said Monday. The money is provided in a contract, not a grant, and ARPA-H officials likened it to a venture capital approach: The four teams will compete alongside each other, and projects showing success or promise will receive full funding over the next five years. The teams may also be combined or lean on each other, depending on their results, Washington said in an interview. The project is ambitious, officials said. But its success could unlock deeper medical advancements. “If you can do this, just think about what you could do for traumatic brain injury, for spinal cord injury,” said ARPA-H’s Dr. Calvin Roberts, an ophthalmologist who will oversee the broader project. “And so those of us who work in the eye, what we love about working in the eye is that it’s just a model for things that are going around elsewhere in the body.” The other teams’ research will include “3-D printed click-lock gel technology with micro-tunneled scaffolds containing stem cell-derived retinal cells,” donor eye procurement and the actual performing of transplant surgeries, according to ARPA-H. The effort to cure blindness, Washington joked, was “biblical” in its enormity — a reference to the Bible story in which Jesus cures a blind man. She and others also likened it to a moonshot, meaning the effort to successfully put Neil Armstrong and Buzz Aldrin on the moon nearly 50 years ago. If curing blindness is similar to landing on the moon, then the space shuttle has already left the launchpad, Washington said. “We have launched,” she said, “and we are on our trajectory.”

I’m A Celeb fans predict star will get the boot after she boasts about buying a Porsche after getting rich overnight'Republicans Pounce': The Single Phrase That Captures the Desperation of the Dead Legacy Media(Reuters) - Billionaire Elon Musk has been using his social media platform X to go to bat for President-elect Donald Trump's cabinet picks and promote his own preferred candidates, advocating for choices he views as change agents who will help remake the U.S. government. In several high-profile cases, however, Musk backed people who either lost out on the roles or withdrew from consideration, suggesting some early limits to the Republican mega donor's influence even as he has emerged as one of Trump's most powerful allies. Musk, who has 206 million followers on X, posted or reposted about Trump's cabinet picks more than 70 times between Nov. 7 and Nov. 20, a Reuters review found. Though the posts represented just a fraction of his more than 2,000 posts during that period, Musk in many cases used them to give attention to Trump's most controversial choices, including former Democratic congresswoman Tulsi Gabbard for U.S. intelligence chief and environmental activist Robert F. Kennedy Jr to lead the top U.S. health agency. Musk most enthusiastically rallied support for Matt Gaetz, the former congressman Trump initially tapped to be his attorney general. In the days following Gaetz's Nov. 13 nomination, Musk posted 37 times about Gaetz or his wife Ginger, mostly in positive terms. That was far more than his posts about Trump's other appointments. Gaetz backed out of consideration on Nov. 21, saying his candidacy had become a distraction for Trump amid allegations of sexual misconduct and illicit drug abuse. He has denied wrongdoing. For Trump's Treasury secretary, Musk pushed for Wall Street financier Howard Lutnick over hedge fund manager Scott Bessent, whom Musk dismissed as "a business-as-usual choice." Bessent got the job anyway. And in a separate fight over Senate leadership, Musk's endorsed candidate also came up short. One Trump ally said those misses showed the limitations of Musk's sway. Musk's reach on X "doesn’t mean he’s an effective advocate for his positions or chosen cabinet members," the Trump ally said. "He's still learning how to operate in politics." Spokespeople for X and Musk did not respond to Reuters requests for comment for this story. Musk, who owns X and rocket company SpaceX and is chief executive of the electric car company Tesla Inc., poured at least $119 million into getting Trump elected and has been a near-constant fixture at Trump's Florida residence, Mar-a-Lago, since his election victory earlier this month. The two men attended an Ultimate Fighting Championship event in New York and a SpaceX launch in Texas, and Musk traveled with Trump to Washington for his meeting with President Joe Biden. On Saturday, Musk reposted a photo that showed him sitting with Trump, Lutnick and Republican Senator Joni Ernst at Mar-a-Lago, where they were discussing cabinet nominees, according to the caption. "Elon Musk and President Trump are great friends and brilliant leaders working together to Make America Great Again. Elon Musk is a once in a generation business leader and our federal bureaucracy will certainly benefit from his ideas and efficiency," said Brian Hughes, a spokesperson for the Trump transition team. Musk's close proximity to Trump has prompted some hand-wringing and complaints from the transition team, who were not accustomed to him being around so much, according to two sources close to Trump staff. Amid increased scrutiny of his unusual role, Musk wrote in a post on X on Nov. 20 that while he had offered his opinion on some candidates, he was not in charge. "Many selections occur without my knowledge and decisions are 100% that of the President," Musk said. EFFICIENCY AND EMOJIS Musk's political posts on X far outnumbered those he used to promote his three businesses, the Reuters review found. He frequently mocks liberals and posts about government waste and Trump's newly created government efficiency panel, which the president-elect tapped Musk and entrepreneur Vivek Ramaswamy to lead. Musk's typical posts consist either of an emoji or a short response to other posts. "Exactly," he wrote on Nov. 14, in response to a post noting that Trump's cabinet picks were "young outsiders" who "skipped the line." He responded with “Awesome” and a smile emoji on Nov. 13 to a post that said: “They put Tulsi Gabbard on a terror watchlist. Now she’s Director of National Intelligence. The biggest ‘F you’ to the Deep State Swamp.” On Nov. 16, as questions swirled about who Trump would pick for his Treasury secretary, Musk wrote on X that Bessent was "a business-as-usual choice," while Lutnick would "actually enact change." Musk also lobbied against Bessent internally, two sources close to Trump said. His efforts fell flat. On Nov. 22, Trump tapped Bessent for the job. Earlier in the month, Musk threw his support behind Republican Senator Rick Scott for Senate majority leader. Trump chose not to weigh in, and Scott ultimately lost to Senator John Thune for the position. One source close to Musk was struck by Musk's willingness to stick with Trump even after he’s been “shut down a couple of times” by the president-elect. "That’s very rare for a billionaire," the source said. "In general when they don’t get what they want, they walk away." The source said Musk was committed to Trump's government efficiency efforts. "He's really focused on the goal," the source said. Another test of Musk's influence lies ahead. Since the election, he has posted six times in support of Trump loyalist Kash Patel running the FBI. Patel, who served on Trump's National Security Council during his first term, has promised to go after politicians and journalists perceived to be enemies of Trump. Musk's X posts make clear that he sees Patel as the best option for change and reform. On Nov. 14, Musk posted a “100%” emoji in response to a clip of Patel saying that he would shut down the FBI’s headquarters on day one of Trump's new administration and reopen it as a “Deep State Museum,” with the caption “Make him FBI director.” (Reporting by Helen Coster in New York and Alexandra Ulmer in San Francisco; Additional reporting by Ned Parker; Editing by Colleen Jenkins and Alistair Bell)

Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged

Commanders place kicker Austin Seibert on injured reserve

Applied Industrial Technologies director sells $605,167 in stockSAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically. Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%. Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record CooperVision revenues, record CooperSurgical revenues and record non-GAAP EPS. We look forward to continued success in fiscal 2025 and thank all of our employees for driving these results." Fourth Quarter Operating Results Revenue of $1,018.4 million, up 10% from last year’s fourth quarter, up 9% in constant currency, up 7% organically. Gross margin of 67% compared with 65% in last year’s fourth quarter driven by price and efficiency gains. On a non-GAAP basis, gross margin was similar to last year at 67%. Operating margin of 19% compared with 15% in last year’s fourth quarter driven by SG&A expense leverage and stronger gross margins. On a non-GAAP basis, operating margin was 26%, up from 24% last year. Interest expense of $27.0 million compared with $26.3 million in last year's fourth quarter. On a non-GAAP basis, interest expense was $25.6 million, down from $26.4 million. Cash provided by operations of $268.1 million offset by capital expenditures of $139.9 million resulted in free cash flow of $128.2 million. Fourth Quarter CooperVision (CVI) Revenue Revenue of $676.4 million, up 9% from last year’s fourth quarter, up 8% in constant currency, up 8% organically. Revenue by category: Revenue by geography: Fourth Quarter CooperSurgical (CSI) Revenue Revenue of $342.0 million, up 12% from last year's fourth quarter, up 12% in constant currency, up 5% organically. Revenue by category: Fiscal Year 2024 Operating Results Revenue of $3,895.4 million, up 8% from fiscal 2023, up 9% in constant currency, up 8% organically. CVI revenue of $2,609.4 million, up 8% from fiscal 2023, up 8% in constant currency, up 9% organically, and CSI revenue $1,286.0 million, up 10% from fiscal 2023, up 11% in constant currency, up 5% organically. Gross margin of 67% compared with 66% in fiscal 2023. Non-GAAP gross margin was 67% compared with 66% in fiscal 2023. Operating margin of 18% compared with 15% in fiscal 2023. Non-GAAP operating margin was 25% compared with 24% in fiscal 2023. Cash provided by operations of $709.3 million offset by capital expenditures of $421.2 million resulted in free cash flow of $288.1 million. Fiscal Year 2025 Financial Guidance The Company initiated its fiscal year 2025 financial guidance. Details are summarized as follows: Fiscal 2025 total revenue of $4,080 - $4,158 million (organic growth of 6% to 8%) CVI revenue of $2,733 - $2,786 million (organic growth of 6.5% to 8.5%) CSI revenue of $1,347 - $1,372 million (organic growth of 4% to 6%) Fiscal 2025 non-GAAP diluted earnings per share of $3.92 - $4.02 Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations. With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance. Reconciliation of Selected GAAP Results to Non-GAAP Results To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period. We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. EPS, amounts and percentages may not sum or recalculate due to rounding. (1) Charges include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees and changes in fair value of contingent considerations, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, other acquired employee related costs, and integration-related professional services, manufacturing integration costs, legal entity rationalization and other integration-related activities. The acquisition and integration-related charges in fiscal 2024 were primarily related to the Cook Medical acquisition and integration expenses. The acquisition and integration-related charges in fiscal 2023 were primarily related to the Generate acquisition and integration expenses. Charges included $2.9 million and $8.4 million related to redundant personnel costs for transitional employees, $0.7 million and $4.5 million of professional services fees, $1.4 million and $1.4 million of manufacturing integration costs, $1.5 million and 1.5 million of inventory fair value step-up amortization, and $0.7 million and $4.1 million of other acquisition and integration-related activities in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million regulatory fees. Charges included $7.5 million and $21.9 million related to redundant personnel costs for transitional employees, $6.5 million and $16.2 million of professional services fees, $2.9 million and $6.5 million of manufacturing integration costs, $3.1 million and $5.0 million of legal entity rationalization costs, $0.9 million and $2.7 million regulatory fees, and $0.6 million and $5.0 million in other acquisition and integration-related activities, in the three and twelve months ended October 31, 2023, respectively. (2) Charges include costs related to product line exits such as inventory write-offs, site closure costs, contract termination costs and specifically-identified long-lived asset write-offs. Charges included $2.3 million of write-offs of long-lived assets and $1.7 million of other costs related to product line exits in the twelve months October 31, 2024. No charge related to product line exits was incurred in the three months ended October 31, 2024. Charges included $3.4 million and $7.9 million of site closure costs related to the exit of the lens care business, $0.4 million and $1.1 million of other costs related to product line exits in the three and twelve months ended October 31, 2023, respectively. The fourth quarter of fiscal 2023 also included $9.8 million of intangible assets impairment charge associated with the discontinuation of certain products. (3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period. (4) Charges represent the costs associated with initiatives to increase efficiencies across the organization and optimize our overall cost structure, including changes to our IT infrastructure and operations, employee severance costs, legal entity and other business reorganizations, write-offs or impairments of certain long-lived assets associated with the business optimization activities. Charges included $1.5 million and $10.6 million of employee severance costs, $1.0 million and $4.1 million related to changes to our IT infrastructure and operation, and $0.4 million and $2.9 million of legal entity and other business reorganizations costs, in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million of other optimization costs. Charges included $1.4 million and $11.3 million of employee severance costs, $1.4 million and $1.9 million of legal entity and other business reorganizations costs, and $0.3 million and $5.9 million related to changes to our IT infrastructure and operations, partially offset by $0.2 million and $0.4 million of other items in the three and twelve months ended October 31, 2023, respectively. (5) Amount represents an accrual for probable payment of a termination fee in connection with an asset purchase agreement in the second quarter of 2023, which was paid in August 2023. (6) Amount represents the release the contingent consideration liability associated with SightGlass Vision's regulatory approval milestone in the first quarter of 2023. (7) Charges include certain business disruptions from natural causes, litigation matters and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables. Charges included $1.5 million and $5.9 million of gains and losses on minority interest investments, $1.4 million and $5.5 million of accretion of interest attributable to acquisition installments payable, $0.6 million and $1.5 million related to legal matters in the three and twelve months ended October 31, 2024, respectively. Charges included $1.6 million and $6.3 million of gains and losses on minority interest investments, and $1.3 million and $4.6 million related to legal matters in the three and twelve months ended October 31, 2023, respectively. The twelve months ended October 31, 2023 also included $1.1 million of other items. (8) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law. Audio Webcast and Conference Call The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its fourth quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com , at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com . Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 2026064. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has a workforce of more than 16,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com. Forward-Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2025 financial guidance are forward looking. In addition, all statements regarding anticipated growth in our revenues, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the California Consumer Privacy Act (CCPA) in the U.S. and the General Data Protection Regulation (GDPR) requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR), and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR); legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance (ESG) issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Contact: Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 ir@cooperco.com THE COOPER COMPANIES, INC. AND SUBSIDIARIES GAAP to Non-GAAP Reconciliation Constant Currency Revenue Growth and Organic Revenue Growth Net Sales

Some Democrats are frustrated over Joe Biden reversing course and pardoning his son HunterUnlike scores of people who for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It’s a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It’s all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person’s response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn’t happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It’s not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn’t respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I’m hoping it’s slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content. Jonel Aleccia, The Associated PressNone

Preview: Borussia Monchengladbach vs. St Pauli - prediction, team news, lineupsTownsquare to Participate in Upcoming Investor Conferences

Malik Nabers says calling the Giants 'soft' was wrong but he doesn't regret speaking outFAIRFIELD — The Rodriguez High School girls basketball team lost at Inderkum in Sacramento, 70-24, Wednesday night. Mia Marquez scored seven points for the Lady Mustangs. Rodriguez fell to 3-3. The Lady Mustangs will be back in action Monday with a 6 p.m. game at Fortune Early College in Sacramento.